Automated Microbiology Market Report 2026

The automated microbiology market size has grown rapidly in recent years. It will grow from $9.4 billion in 2025 to $10.63 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to increasing clinical testing volumes, rising demand for faster diagnostic results, expansion of hospital laboratory infrastructure, shortages of skilled lab personnel, adoption of standardized diagnostic protocols.

The automated microbiology market size is expected to see rapid growth in the next few years. It will grow to $17.19 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing investments in smart laboratories, growing demand for rapid infectious disease diagnostics, expansion of molecular microbiology applications, rising adoption of data-integrated laboratory systems, increasing focus on diagnostic accuracy. Major trends in the forecast period include increasing adoption of fully automated microbiology systems, rising use of AI-driven pathogen identification, growing integration of lims platforms, expansion of high-throughput diagnostic testing, enhanced focus on laboratory workflow automation.

The increasing demand for rapid and accurate diagnostics is expected to drive the growth of the automated microbiology market in the coming years. Rapid and accurate diagnostics involve medical testing methods that quickly and precisely detect infections or diseases, allowing for timely and effective treatments. The growing need for rapid and accurate diagnostics is fueled by the necessity for early disease detection to prevent complications and enhance patient outcomes while minimizing waiting time for results. Automated microbiology addresses this demand by providing high-throughput, standardized, and error-reduced testing, ensuring faster results and improved patient care. For example, in 2024, according to the World Health Organization, a Switzerland-based national agency reported that the initial diagnostic test was conducted for 54% (4.5 million) of the 8.3 million people newly diagnosed with TB in 2024, up from 48% (of 8.2 million) in 2023. Consequently, the rising demand for rapid and accurate diagnostics is driving the growth of the automated microbiology market.

Major companies in the automated microbiology market are concentrating on developing advanced technologies, such as matrix-assisted laser desorption/ionization (MALDI) biotyper systems, to improve the speed and accuracy of microbial identification. This mass spectrometry-based method identifies microorganisms, including bacteria and fungi, by analyzing their distinct protein profiles. For example, in April 2024, Bruker Corporation, a US-based manufacturer of scientific instruments for molecular and materials research, introduced the MBT Pathfinder IVD robot for automated MALDI Biotyper target preparation. This innovation automates the preparation of targets for MALDI biotyper analysis, enhancing efficiency in clinical workflows. It simplifies sample loading, matrix application, and plate preparation, allowing faster and more precise identification of microorganisms.

In January 2024, Rapid Micro Biosystems, a US-based provider of automated microbial detection systems, formed a partnership with Samsung Biologics to implement the Growth Direct® platform for automating microbial quality control workflows. Through this collaboration, the companies aim to improve efficiency, data integrity, and throughput in QC microbiology laboratories. This partnership highlights the automated microbiology market’s increasing focus on laboratory automation, rapid microbial detection, and streamlined biopharmaceutical quality control processes. Samsung Biologics is a South Korea-based contract development and manufacturing organization (CDMO).

Major companies operating in the automated microbiology market are Thermo Fisher Scientific Inc, Danaher Corporation, Becton Dickinson and Company, bioMérieux SA, Abbott Laboratories, Merck KGaA, Agilent Technologies Inc, Sysmex Corporation, Bio-Rad Laboratories Inc, PerkinElmer Inc, HORIBA Ltd, DiaSorin SpA, Neogen Corporation, Rapid Micro Biosystems Inc, Bruker Corporation, Tecan Group AG, Roche Diagnostics International AG, QIAGEN NV, Illumina Inc, Luminex Corporation.

North America was the largest region in the automated microbiology market in 2025. The regions covered in the automated microbiology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automated microbiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the automated microbiology market by increasing costs of imported diagnostic instruments, robotic sample handlers, molecular reagents, and laboratory automation software. Clinical laboratories and pharmaceutical facilities in North America and Europe are most affected due to reliance on imported systems, while Asia-Pacific faces cost pressure on manufacturing and system integration. These tariffs are raising capital expenditure and slowing laboratory upgrades. However, they are also encouraging regional production of diagnostic instruments, localized reagent manufacturing, and development of cost-optimized automation platforms.

The automated microbiology market research report is one of a series of new reports that provides automated microbiology market statistics, including automated microbiology industry global market size, regional shares, competitors with a automated microbiology market share, detailed automated microbiology market segments, market trends and opportunities, and any further data you may need to thrive in the automated microbiology industry. This automated microbiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Automated microbiology involves the use of automated systems and technologies to carry out microbiological tasks that were traditionally done manually. The aim is to increase efficiency, minimize human error, improve reproducibility, and accelerate the diagnostic process, particularly in clinical microbiology laboratories.

The primary products in automated microbiology include instruments, reagents and kits, and software. Instruments generally refer to the specialized equipment used for automated microbiological testing, analysis, and diagnostics. They are available in both fully automated and semi-automated versions and employ a range of diagnostic technologies, such as DNA sequencing, DNA and RNA probe techniques, detection methods, monoclonal antibodies, and immunoassays. Applications cover biopharmaceutical manufacturing, clinical diagnostics, environmental and water testing, food and beverage analysis, and more, catering to end users like pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, academic and research institutions, and others.

The automated microbiology market includes of revenues earned by entities by providing services such as microbial identification, rapid molecular diagnostics, and others. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The automated microbiology market consists of sales of laboratory automation systems, automated microbiology panels, and automated microbial detection systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.